2. Academic Validation
  3. Discovery of novel selective inhibitors for EGFR-T790M/L858R

Discovery of novel selective inhibitors for EGFR-T790M/L858R

  • Bioorg Med Chem Lett. 2012 Feb 1;22(3):1365-70. doi: 10.1016/j.bmcl.2011.12.067.
Fang Bai 1,  Hongyan Liu,  Linjiang Tong,  Wei Zhou,  Li Liu,  Zhenjiang Zhao,  Xiaofeng Liu,  Hualiang Jiang,  Xicheng Wang,  Hua Xie,  Honglin Li
Affiliations

Affiliation

  • 1 Faculty of Chemical, Environmental and Biological Science and Technology, Dalian University of Technology, Dalian 116023, China.
PMID: 22227214 DOI: 10.1016/j.bmcl.2011.12.067
Abstract

Through a receptor-based and ligand-based combined virtual screening protocol, 21 novel compounds covering 15 scaffolds were identified as novel inhibitors for EGFR-T790M/L858R, among which, 12 of them were identified as selective inhibitors for EGFR-T790M/L858R to wild-type EGFR, and 5 of them exhibited 'dual-effective' to wild-type and mutant EGFR. Meanwhile, their antiproliferative effects toward EGFR high-expressing human lung Cancer cell (A549), epidermoid carcinoma cell (A431), and the mutant EGFR-dependent cell (NCI-H1975) were also evaluated.

Figures
Products